TORONTO - Canopy Rivers Inc. (“Rivers” or the “Company”) (TSX: RIV) (OTC: CNPOF) today announced that it has entered into a definitive agreement (the “Arrangement Agreement”) with Canopy Growth Corporation (“Canopy Growth”) (TSX: WEED) (NASDAQ: CGC) pursuant to which, among other things, Rivers will transfer three portfolio assets to Canopy Growth in exchange for $115 million in cash and 3,750,000 common shares of Canopy Growth and the cancellation of all 36,468,318 Multiple Voting Shares (“MVS”) and the 15,223,938 Subordinate Voting Shares (“SVS”) of Rivers held by Canopy Growth (collectively, the “Transaction”). On closing, the Transaction will result in Rivers becoming a widely-held company and will unlock substantial value, providing Rivers with significant additional cash resources and allowing it to pursue opportunities in the global cannabis market, including the United States (“U.S.”). The Company believes that its significant cash position and single class share structure will make it an attractive transaction partner for cannabis operators, including those in the U.S., looking for access to capital and a path to liquidity. The Transaction will proceed by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario).
“This is a transformative transaction for our Company that we believe provides substantial value to our shareholders through an enhanced cash position and strategic flexibility, and the collapse of our dual class share structure,” said Narbé Alexandrian, President and CEO, Rivers. “Following the closing of the Transaction, we intend to shift our focus to pursuing other opportunities in the global cannabis market, where we believe that our new strategic focus and substantial balance sheet will allow us to successfully execute our revamped strategic plan.”
“As a long-time shareholder of Rivers, I am pleased to support this transaction”, said Jason Wild, chairman of JW Asset Management which, on closing, will own 23.9% of the common equity of the Company. “As an active investor in the U.S. cannabis market, JW Asset Management recognizes the generational opportunity for value creation in the world’s largest and most attractive cannabis market. With a significant infusion of cash and liquid securities, and a new strategic focus, we believe that Rivers will be well-positioned to further explore and potentially capitalize on this vast opportunity.”
“The financial and strategic merits of the Transaction to the Company and our minority shareholders are clear,” said Joseph Mimran, Chair of the special committee of independent directors (the “Special Committee”) that Rivers’ board of directors (the “Board”) established in connection with the Transaction. “On behalf of the Board, we look forward to writing the next chapter in Rivers’ history.”
The Transaction will include the following steps:
Concurrent with completion of the Transaction, Canopy Growth’s nominees on the Company’s board of directors will resign from the Board. The Company intends to replace the departing directors with new directors having skills and experience that complement those of the remaining directors, taking into account the Company’s new strategy and focus.
Under the terms of the Arrangement Agreement, Rivers will be exiting the Transferred Assets at a substantial premium to the amounts originally invested by the Company. The aggregate Transaction value represents a total return on invested capital (“ROIC”) of 5.6x and a combined internal rate of return (“IRR”) of approximately 101%.1
The Transaction is also expected to significantly strengthen Rivers’ balance sheet and liquidity position. The Company estimates that cash proceeds (not including the value of the Canopy Growth shares issuable to Rivers) from the disposition of the Transferred Assets, net of the associated tax liability and Transaction costs, will be approximately $87.2 million.2 Taking into account the Company’s current adjusted cash balance of $31.0 million,3 this represents a pro forma cash balance of $118.2 million. Based on the closing price of the Canopy Growth common shares on December 18, 2020, the 3,750,000 shares were worth approximately $124.8 million. On a pro forma basis, cash and liquid securities per share (including the implied value of the Canopy Growth common shares as at December 18, 2020) would be $1.74 assuming completion of the Transaction.4
Rivers believes the Transaction will propel the Company to its next phase of growth. The Company believes the Transaction will provide the following benefits, among others:
Strategic Flexibility: Following completion of the Transaction, the Company will have the freedom to consider and execute on new opportunities, including potentially in the U.S., the world’s largest and most attractive cannabis market. As such opportunities may be inconsistent with the policies of the Toronto Stock Exchange (“TSX”), to the extent the Company intends to pursue such opportunities, the Company may de-list from the TSX following completion of the Transaction and list its securities on a stock exchange that permits such activities. In addition, should the Company pursue such opportunities, the Company will address the impact of any such activities on existing business relationships, including with portfolio companies, suppliers, lenders and other third parties.
Financial Strength: Upon closing of the Transaction, the Company is expected to have a balance sheet that compares favourably with many peers in the cannabis industry, with approximately $243 million in cash and liquid securities on a pro forma basis.5 This will improve Rivers’ liquidity in the near term, and is expected to position the Company as an attractive investment, acquisition and/or merger partner.
Favourable Transaction Economics:
Elimination of the Dual Class Share Structure: Upon closing of the Transaction, the Company and minority shareholders will derive a number of benefits associated with the elimination of the Company’s dual class share structure, including: enhanced strategic flexibility, given the absence of a controlling shareholder; proportionate voting and economic interests of the Company for all shareholders; and a more attractive share capital structure for purposes of investments, acquisitions and capital-raising.
Rivers will convene a special meeting of shareholders (the “Meeting”) in early 2021 to approve the Transaction. The Transaction will require approval of at least (a) two-thirds of the votes cast by both: (i) Canopy Growth as the holder of all of the MVS; and (ii) Rivers shareholders that hold SVS, and (b) a simple majority of the votes cast by holders of SVS, excluding the votes attaching to the SVS held by Canopy Growth. Pursuant to the Arrangement Agreement, Canopy Growth has agreed to vote all of its MVS and SVS in favour of the Transaction.
Funds managed by JW Asset Management, the Company’s largest holder of SVS, and each of the Company’s directors and executive officers, which in aggregate represent approximately 24.5% of the outstanding SVS, excluding the SVS held by Canopy Growth, have entered into voting support agreements agreeing to vote their SVS in favour of the Transaction.
Completion of the Transaction is also subject to other customary approvals and conditions, including approval from the court, TSX and Nasdaq. The Transaction is expected to close in the first quarter of calendar year 2021.
The Board, other than directors who recused themselves and abstained from voting due to their role as a director, officer and/or nominee of Canopy Growth or TerrAscend, unanimously approved the Arrangement Agreement following a unanimous recommendation of the Special Committee, which was comprised of directors independent of Canopy Growth, TerrAscend and management of Rivers. Both the Special Committee and the Board determined that the Transaction is fair to, and in the best interests of, the Company and unanimously recommend that shareholders vote in favour of the Transaction.
The entering into the Arrangement Agreement was preceded by a review and evaluation of the Transaction by the Special Committee, which was advised by experienced, qualified and independent financial and legal advisors. In conducting its review and evaluation of the Transaction, the Special Committee was actively involved in, and supervised, negotiations with Canopy Growth.
In connection with its review and evaluation of the Transaction, the Special Committee engaged Echelon Wealth Partners Inc. (“Echelon”) as an independent valuator to prepare a formal valuation of the Transferred Assets pursuant to Multilateral Instrument 61-101 and a long-form fairness opinion. The Special Committee received the formal valuation from Echelon which concluded that, subject to the scope of review, assumptions, limitations and qualifications set forth therein, as of December 21, 2020, the consideration being received by the Company was above the midpoint of the valuation range determined by Echelon Partners. The Special Committee also received an opinion from Echelon that, subject to the scope of review, assumptions, limitations and qualifications in such opinion, as of December 21, 2020, the consideration to be received by the Company pursuant to the Transaction is fair, from a financial point of view, to the Company.
The Special Committee engaged Eight Capital as financial advisor to assist in its review, evaluation and negotiation of the Transaction. The Special Committee received an opinion from Eight Capital that, subject to the scope of review, assumptions, limitations and qualifications in such opinion, as of December 21, 2020, the consideration to be received by the Company pursuant to the Transaction is fair, from a financial point of view, to the Company.
For further information on the terms and conditions of the Transaction, please refer to the Arrangement Agreement which will be available on SEDAR at www.sedar.com. Full details of the Transaction, including the Echelon formal valuation and fairness opinion and the Eight Capital fairness opinion, will be included in a management information circular of the Company to be delivered to the Company’s shareholders in the coming weeks.
Eight Capital is serving as financial advisor and Davies Ward Phillips & Vineberg LLP is acting as legal counsel to the Special Committee. Echelon served as independent valuator to the Special Committee.
Canopy Rivers is a venture capital firm specializing in cannabis with a portfolio of 18 companies across various segments of the cannabis value chain. We believe that bringing together people, capital, and ideas raises the potential of the entire cannabis industry. By leveraging our industry insights, in-house expertise, and thesis-driven approach to investing, we aim to provide shareholders with exposure to specialized and disruptive cannabis companies. Our mission is to invest in innovators across the cannabis value chain, help them grow, and ultimately create value by guiding these companies towards a monetization event. Together with our portfolio, we are helping build the cannabis industry of tomorrow, today.
This news release contains statements which constitute "forward-looking information" within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. To the extent any forward-looking information in this news release constitutes "financial outlooks" within the meaning of applicable Canadian securities laws, the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions, and forward-looking information in this news release includes, but is not limited to, information and statements regarding: whether and when the Transaction will be consummated; the anticipated benefits of the Transaction, including the implied value of the Transaction (including ROIC and IRR), the Company’s expectation that the Transaction will significantly strengthen the Company’s balance sheet and liquidity position, the anticipated cash proceeds from the Transaction net of the associated tax liability and transaction costs, the Company’s pro forma cash balance and liquid assets upon completion of the Transaction, the Company’s anticipated cash per share on a pro forma basis and including the value of the Canopy Growth common shares, the Company’s expectation that its balance sheet will compare favourably with peers in the industry, the Company’s expectation that the Transaction will be immediately accretive to minority shareholders and the anticipated benefits associated with the elimination of the Company’s dual class share structure; the Company’s intention to invest, acquire and/or merge with operating U.S. cannabis companies and the value to be derived therefrom; the possibility that the Company may de-list from the TSX following completion of the Transaction and list its securities on a stock exchange that permits investments in and/or acquisitions of U.S. cannabis companies; the anticipated timing of the Meeting and the requisite shareholder approvals to be obtained at the Meeting; the Company obtaining and/or satisfying customary approvals and conditions, including court approval for the Transaction; and expectations for other economic, business, and/or competitive factors.
Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein.
Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the parties’ ability to consummate the Transaction; the ability to receive, in a timely manner and on satisfactory terms, all necessary regulatory, court, shareholder, and other third party approvals; the ability of the parties to satisfy, in a timely manner, all other conditions to the closing of the Transaction; the potential impact of the announcement or consummation of the Transaction on relationships, including with regulatory bodies, stock exchanges, lenders, employees and competitors; the diversion of management time on the Transaction; assumptions concerning the Transaction and the operations and capital expenditure plans of the Company following completion of the Transaction; credit, liquidity and additional financing risks for the Company and its investees; stock market volatility; regulatory and licensing risks; changes in cannabis industry growth and trends; changes in the business activities, focus and plans of the Company and its investees and the timing associated therewith; the Company's actual financial results and ability to manage its cash resources; changes in general economic, business and political conditions, including challenging global financial conditions and the impact of the novel coronavirus pandemic; competition risks; potential conflicts of interest; the regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in applicable laws; changes in the global sentiment towards, and public opinion of, the cannabis industry; divestiture risks; and the other risk factors more fully described in the Company's AIF, filed with the Canadian securities regulators and available on the Company's profile on SEDAR at www.sedar.com.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
SOURCE Canopy Rivers Inc.
For further information:
Senior Manager, Public Relations & Communications
1Total returns include historical receipts of royalty payments of $4.1 million up to December 18, 2020, relating to the Company’s royalty investment in The Tweed Tree Lot and the anticipated receipt of interest receivable of $1.0 million in January 2021 relating to the Company’s loan investment in TerrAscend Canada.
2The estimated tax liability and transaction costs are based on a number of assumptions and estimates, and will be refined upon further review and analysis and as additional information becomes available.
3Existing cash balance of $33.8 million adjusted for $2.8 million in commitments to existing portfolio companies.
4Based on 139.8 million pro forma basic shares outstanding.
5Based on estimated net cash proceeds from the Transaction of $87.2 million, the Company’s current adjusted cash balance of $31.0 million, and the implied value of 3.75 million Canopy Growth common shares based on the closing price on December 18, 2020.
6Based on the closing price of Canopy Growth common shares on December 18, 2020.
Please select how you would like to hear from RIV Capital:
We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.
Yes, I’m definitely at least twenty-one (21) years of age or am otherwise a qualified patient.